A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc)

被引：0
|
作者：
Davelaar, John
Tighiouart, Mourad
Hendifar, Andrew Eugene
Osipov, Arsen
Moshayedi, Natalie
Placencio-Hickok, Veronica
Bhowmick, Neil
Gong, Jun
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Samuel Oschin Canc Ctr, Los Angeles, CA 90048 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS636
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS636
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P plus GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis
    Yoo, Changhoon
    Jeong, Hyehyun
    Chae, Heejung
    Cheon, Jaekyung
    Chon, Hong Jae
    Ryu, Hyewon
    Kim, Il-Hwan
    Jeong, Jae Ho
    Kim, Kyu-Pyo
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] nab-Paclitaxel (nab-P) plus gemcitabine (Gem) for patients with advanced pancreatic cancer who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction: a phase I safety and pharmacokinetics study
    Riess, H.
    Kunzmann, V.
    Philip, P.
    Seufferlein, T.
    McGovern, D.
    Chen, P.
    Romano, A.
    Ramanathan, R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [33] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [34] Tumor burden reduction between primary and metastatic sites in advanced pancreatic cancer patients (pts) undergoing chemotherapy with nab-paclitaxel (Nab-P) and gemcitabine (Gem)
    Ventriglia, J.
    Laterza, M. M.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Diana, A.
    Troiani, T.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [35] Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Renouf, Daniel John
    Loree, Jonathan M.
    Knox, Jennifer J.
    Kavan, Petr
    Jonker, Derek J.
    Welch, Stephen
    Couture, Felix
    Lemay, Frederic
    Tehfe, Mustapha
    Harb, Mohammed
    Aucoin, Nathalie
    Ko, Yoo-Joung
    Tang, Patricia A.
    Topham, James T.
    Jia, Shidong
    Du, Pan
    Schaeffer, David F.
    Gill, Sharlene
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)
    Pascal, Hammel
    Jill, Lacy
    Fabienne, Portales
    Alberto, Sobrero
    Beatriz, Garca-Paredes
    Edward, Kim
    Fernando, Rivera
    Jose Luis, Manzano
    Eric, Terrebonne
    Venu, Bathini
    Scot, Dowden
    Jamil, Asselah
    Jack, Shiansong Li
    Thomas, Nydam
    Louis, Kayitalire
    Philip, Philip
    ANNALS OF ONCOLOGY, 2016, 27 : 78 - 79
  • [37] LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).
    Philip, Philip Agop
    Lacy, Jill
    Dowden, Scot D.
    Sastre, Javier
    Bathini, Venu Gopal
    Cardin, Dana Backlund
    Ma, Wen Wee
    Sobrero, Alberto F.
    Koski, Sheryl L.
    Borg, Christophe
    Tonini, Giuseppe
    Rivera, Fernando
    Hwang, Jimmy J.
    Knoble, Jeanna L.
    Al Baghdadi, Tareq
    Saif, Wasif M.
    Meiri, Eyal
    Kayitalire, Louis
    Li, Jack
    Hammel, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [38] The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Renouf, D. J.
    Knox, J. J.
    Kavan, P.
    Jonker, D.
    Welch, S.
    Couture, F.
    Lemay, F.
    Tehfe, M.
    Harb, M.
    Aucoin, N.
    Ko, Y-J.
    Tang, P.
    Ramjeesingh, R.
    Meyers, B. M.
    Kim, C.
    Schaeffer, D. F.
    Loree, J.
    Gill, S.
    Tu, D.
    O'Callaghan, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1195 - S1195
  • [39] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
    Tempero, M. A.
    Cardin, D.
    Biankin, A.
    Goldstein, D.
    Moore, M.
    O'Reilly, E. M.
    Philip, P.
    Riess, H.
    Macarulla, T.
    Yung, L.
    Wei, X.
    Lu, B.
    PANCREAS, 2014, 43 (08) : 1416 - 1416
  • [40] The Canadian Cancer Trials Group PA. 7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Renouf, Daniel John
    Dhani, Neesha C.
    Kavan, Petr
    Jonker, Derek J.
    Wei, Alice Chia-chi
    Hsu, Tina
    Tang, Patricia A.
    Graham, Barbara
    Gallinaro, Lisa
    Hasan, Tasnia
    Li, Weiwei
    Hart, Kate
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345